Patients with Huntington’s disease, a fatal genetic illness that causes the breakdown of nerve cells in the brain, have up to 80 percent less cancer than the general population.
Northwestern Medicine scientists have discovered why Huntington’s is so toxic to cancer cells and harnessed it for a novel approach to treat cancer, a new study reports.
Huntington’s is caused by an over abundance of a certain type of repeating RNA sequences in one gene, huntingtin, present in every cell. The defect that causes the disease also is highly toxic to tumor cells. These repeating sequences — in the form of so-called small interfering RNAs — attack genes in the cell that are critical for survival. Nerve cells in the brain are vulnerable to this form of cell death, however, cancer cells appear to be much more susceptible.
“This molecule is a super assassin against all tumor cells,” said senior author Marcus Peter, the Tom D. Spies Professor of Cancer Metabolism at Northwestern University Feinberg School of Medicine. “We’ve never seen anything this powerful.”
Huntington’s disease deteriorates a person’s physical and mental abilities during their prime working years and has no cure.
The study will be published Feb. 12 in the journal EMBO Reports.
To test the super assassin molecule in a treatment situation, Peter collaborated with Dr. Shad Thaxton, associate professor of urology at Feinberg, to deliver the molecule in nanoparticles to mice with human ovarian cancer. The treatment significantly reduced the tumor growth with no toxicity to the mice, Peter said. Importantly, the tumors did not develop resistance to this form of cancer treatment.
Peter and Thaxton are now refining the delivery method to increase its efficacy in reaching the tumor. The other challenge for the scientists is figuring out how to stabilize the nanoparticles, so they can be stored.
First and co-corresponding author Andrea Murmann, research assistant professor in medicine at Feinberg, also used the molecule to treat human and mouse ovarian, breast, prostate, liver, brain, lung, skin and colon cancer cell lines. The molecule killed all cancer cells in both species.
The Huntington’s cancer weapon was discovered by Murmann, who had worked with Peter on earlier research that identified an ancient kill-switch present in all cells that destroys cancer.
“I thought maybe there is a situation where this kill switch is overactive in certain people, and where it could cause loss of tissues,” Murmann said. “These patients would not only have a disease with an RNA component, but they also had to have less cancer.”
She started searching for diseases that have a lower rate of cancer and had a suspected contribution of RNA to disease pathology. Huntington’s was the most prominent.
When she looked at the repeating sequences in huntingtin, the gene that causes the disease, she saw a similar composition to the earlier kill switch Peter had found. Both were rich in the C and G nucleotides (molecules that form the building blocks of DNA and RNA).
“Toxicity goes together with C and G richness,” Murmann said. “Those similarities triggered our curiosity.”
In the case of people who have Huntington’s, the gene huntingtin has too many repeating sequences of the triplet sequence CAG. The longer the repeating sequence, the earlier they will develop the disease.
“We believe a short-term treatment cancer therapy for a few weeks might be possible, where we could treat a patient to kill the cancer cells without causing the neurological issues that Huntington’s patients suffer from,” Peter said.
Peter also is co-leader of the Translational Research in Solid Tumors Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
Huntington’s patients have a lifetime exposure to these toxic RNA sequences, but generally don’t develop symptoms of the disease until age 40, he noted.
Every child of a parent with Huntington’s has 50/50 chance of carrying the faulty gene. Today, there are approximately 30,000 symptomatic Americans and more than 200,000 at-risk of inheriting the disease.
Learn more: Huntington’s disease provides new cancer weapon
The Latest on: Cancer therapy
via Google News
The Latest on: Cancer therapy
- Val Kilmer Gives Health Update After Tracheotomy, Throat Cancer Treatmenton August 8, 2020 at 11:02 am
Batman Forever star Val Kilmer is giving an update on his health after undergoing a tracheotomy as part of his overall treatment for throat cancer. The actor, who reprises his role as LT Tom "Iceman" ...
- 'Heartless' officials bar fiance of cancer sufferer from coming into Canadaon August 8, 2020 at 7:00 am
By Jonathan Bradley A Canadian woman is fighting to get her British fiance into the country as she undergoes cancer treatment. Sarah Campbell, an art therapy graduate student from Stratford, Ont., was ...
- New type of immunotherapy shows promise for advanced skin canceron August 7, 2020 at 11:44 am
A new type of immunotherapy for the skin cancer malignant melanoma shows promising results. Three severely ill patients are now long-term survivors.
- Breakthrough In Devil's Cancer Treatment Could Benefit Human Cancer Therapies Tooon August 7, 2020 at 7:00 am
Tasmanian devils have been battling with a bizarre form of cancer that is contagious and spreads like wildfire. It’s passed on when the animals bite each o ...
- Researchers develop promising new treatment of advanced skin canceron August 7, 2020 at 6:39 am
A new type of immunotherapy for the skin cancer malignant melanoma shows promising results. Three severely ill patients are now long-term survivors. The study, published in OncoImmunology, is the ...
- Medical trial aims to identify those at risk of heart damage following cancer treatmenton August 7, 2020 at 4:51 am
The Murdoch Children's Research Institute (MCRI) is recruiting patients for a new national trial aiming to identify those at risk of heart damage following cancer treatment.
- HNF4α regulates sulfur amino acid metabolism and confers sensitivity to methionine restriction in liver canceron August 7, 2020 at 2:38 am
The molecular determinants of differential responses of different cancer cells to methionine restriction are poorly understood. Here the authors show that hepatocyte nuclear factor 4α regulates sulfur ...
- Black Children With Cancer Less Likely To Receive Radiation Treatments Than White Childrenon August 6, 2020 at 9:54 pm
New research reveals glaring racial disparities among pediatric patients when it comes to gaining access to subsidized photon and proton radiotherapies for cancer treatment ...
- Gene Therapy Promising in BCG-Unresponsive Bladder Canceron August 6, 2020 at 2:40 pm
An investigative intravesical viral gene therapy may offer a bladder-sparing alternative for some patients with high-grade, nonmuscle invasive bladder cancer who have few options, results from a phase ...
- New RTP startup backed by Eshelman aims at cancer treatmenton August 6, 2020 at 12:44 pm
With financial backing by one of North Carolina's most influential venture capitalists, a new Research Triangle Firm is taking technology out of G1 Therapeutics to develop its own cancer treatment.
via Bing News